🇺🇸 FDA
Patent

US 9751878

Tetrahydronaphthyridine somatostatin receptor 5 antagonists

granted A61PA61P3/00A61P3/10

Quick answer

US patent 9751878 (Tetrahydronaphthyridine somatostatin receptor 5 antagonists) held by Takeda Pharmaceutical Company Limited expires Mon Aug 31 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Sep 05 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 31 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61P, A61P3/00, A61P3/10, A61P43/00, A61P9/00